GT Biopharma
GTBP0.32610.00% ( 0.0000 )
GT Biopharma (GTBP)
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-sp...
- Open
- 0.3235
- High
- 0.3314
- Low
- 0.3201
- Prev. Close
- 0.3261
- Volume
- 84.37K
- Turnover
- 27.67K
- Avg Price
- 0.3280
- Bid/Ask Ratio
- --
- Amplitude
- 3.47%
- 52wk High
- 1.8900
- Volume Ratio
- 1.19
- Turnover Ratio
- 0.25%
GT Biopharma Analyst Rating
View MoreForecast & Rating
May 15, 2026Price forecast
$3.00819.96%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PR Newswire · Jul 6 at 10:19 AM
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- PUBT · Jun 18 at 03:46 PM
GT Biopharma announces annual shareholder meeting
- benzinga_article · Jun 1 at 07:06 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga_article · Jun 1 at 06:31 AM
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
- Unusual Whales · May 29 at 08:02 AM
The $13 Million Company Teaching the Immune System to Hunt Cancer
- PR Newswire · May 18 at 01:22 PM
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
